Premium
The Oestrogenic Effects of Ethinyl Oestradiol/Polyoestradiol Phosphate and Estramustine Phosphate in Patients with Prostatic Carcinoma A Comparative Study of Oestrogen Sensitive Liver Proteins, Gonadotrophins and Prolactin
Author(s) -
DAEHLIN L.,
DAMBER J.E.,
SCHOULTZ B.,
BERGMAN B.
Publication year - 1986
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1986.tb09095.x
Subject(s) - prolactin , medicine , estramustine , endocrinology , orchiectomy , prostate , hormone , cancer , prostate disease
Summary— Thirty previously untreated patients with carcinoma of the prostate were prospectively randomised to one of the following treatments: (1) ethinyl oestradiol (Etivex®) combined with polyoestradiol phosphate (Estradurin®); (2) estramustine phosphate (Estracyt®); (3) bilateral orchiectomy. Oestrogenic effects were measured by blood levels of pregnancy zone protein, sex hormone binding globulin, LH, FSH and prolactin. During a follow‐up period of 6 months, estramustine phosphate and ethinyl oestradiol/polyoestradiol phosphate induced comparable changes in these proteins, suggesting comparable oestrogenic effects of these two forms of treatment in patients with prostatic carcinoma.